A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.

Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Patricia LoRusso(Yale Cancer Center), Stefan Englert(AbbVie (Germany)), Andrew J. Souers(AbbVie (United States)), Afshin Dowlati(University Hospitals of Cleveland), Sheryl Coppola(AbbVie (United States)), Benedito A. Carneiro(Brown University), Young Kwang Chae(Northwestern University), John D. Powderly(Carolina BioOncology Institute), Sudhir Penugonda(ClearMotion (United States)), Albiruni Ryan Abdul Razak(Roche (Switzerland)), Jeannine Villella(Northwell Health), Andrew C. Phillips(AbbVie (United States)), Zeena Salman(Revolution Medicines (United States))
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.3015
Cited by 33

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k